Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity ...
The February 25 earnings call is a key date for investors. Management must demonstrate the extent to which the new reimbursement models are affecting the balance sheet and whether current cost ...
CANTON, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results